Corvus Pharmaceuticals (CRVS) Other financing activities (2015 - 2026)

Corvus Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 379.93% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 171.81% increase from a year earlier, with the FY2025 full-year figure at $35.7 million, up 52466.18% from the prior year.
• Other financing activities improved to $1.3 million in Q1 2026 per CRVS's latest filing, from $67750.0 in the prior quarter.
• Across five years, Other financing activities topped out at $3.9 million in Q3 2024 and bottomed at -$8.9 million in Q4 2024.
• The 4-year median for Other financing activities is $173375.0 (2025), against an average of -$163561.8.
• Across the five-year window, Other financing activities surged 48687.5% in 2024 and tumbled 98.26% in 2025, its largest moves.
• Year by year, Other financing activities stood at $8000.0 in 2023, then tumbled by 110925.0% to -$8.9 million in 2024, then surged by 100.76% to $67750.0 in 2025, then jumped by 1876.38% to $1.3 million in 2026.
• Per Business Quant, the three latest CRVS Other financing activities figures stand at $1.3 million (Q1 2026), $67750.0 (Q3 2025), and $2.0 million (Q2 2025).